PL3429622T3 - Leczenie ciężkiego pozaszpitalnego zapalenia płuc - Google Patents

Leczenie ciężkiego pozaszpitalnego zapalenia płuc

Info

Publication number
PL3429622T3
PL3429622T3 PL17713592T PL17713592T PL3429622T3 PL 3429622 T3 PL3429622 T3 PL 3429622T3 PL 17713592 T PL17713592 T PL 17713592T PL 17713592 T PL17713592 T PL 17713592T PL 3429622 T3 PL3429622 T3 PL 3429622T3
Authority
PL
Poland
Prior art keywords
treatment
acquired pneumonia
community acquired
severe community
severe
Prior art date
Application number
PL17713592T
Other languages
English (en)
Polish (pl)
Inventor
Patrick Langohr
Andrea Wartenberg-Demand
Ulrike Wippermann
Benjamin Daelken
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of PL3429622T3 publication Critical patent/PL3429622T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17713592T 2016-03-14 2017-03-13 Leczenie ciężkiego pozaszpitalnego zapalenia płuc PL3429622T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16160175 2016-03-14
EP16185173 2016-08-22
PCT/EP2017/055838 WO2017157850A1 (en) 2016-03-14 2017-03-13 Treatment of severe community acquired pneumonia
EP17713592.8A EP3429622B1 (en) 2016-03-14 2017-03-13 Treatment of severe community acquired pneumonia

Publications (1)

Publication Number Publication Date
PL3429622T3 true PL3429622T3 (pl) 2021-11-02

Family

ID=58413057

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17713592T PL3429622T3 (pl) 2016-03-14 2017-03-13 Leczenie ciężkiego pozaszpitalnego zapalenia płuc

Country Status (10)

Country Link
US (4) US20190076523A1 (enExample)
EP (2) EP3851123A1 (enExample)
JP (1) JP7041634B2 (enExample)
CN (1) CN108778333A (enExample)
AU (1) AU2017233923B2 (enExample)
CA (1) CA3013849A1 (enExample)
ES (1) ES2881201T3 (enExample)
PL (1) PL3429622T3 (enExample)
RU (1) RU2735680C2 (enExample)
WO (1) WO2017157850A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747903A1 (en) 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
CA3195385A1 (en) 2020-11-19 2022-05-27 Biotest Ag Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19
CN112485448B (zh) * 2020-11-20 2021-08-24 浙江大学 Nmi蛋白作为生物靶标在制备成人社区获得性肺炎严重程度及预后评估试剂盒的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001319A1 (en) 1977-08-18 1979-04-04 Beecham Group Plc Process for the preparation of hydroxyphenyl hydantoin and of hydroxyphenyl glycine, and compounds thus obtained
DE2901822A1 (de) 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
JP2010512350A (ja) * 2006-12-11 2010-04-22 ダラグレキュル・アンパルトセルスカブ ホスホマイシンの肺投与により細菌感染を伴う嚢胞性線維症または肺炎を処置するための方法
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
US20130196310A1 (en) * 2008-05-20 2013-08-01 Rapid Pathogen Screening, Inc. Method and Device for Combined Detection of Viral and Bacterial Infections
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
GB201006753D0 (en) * 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
RU2470664C2 (ru) * 2010-08-23 2012-12-27 Андрей Германович Лютов Способ получения иммуноглобулина для внутривенного введения, обогащенного иммуноглобулином м, и препарат, полученный этим способом
CN104254542A (zh) 2012-03-09 2014-12-31 瑞士杰特贝林生物制品有限公司 包含分泌-样免疫球蛋白的组合物

Also Published As

Publication number Publication date
JP7041634B2 (ja) 2022-03-24
CA3013849A1 (en) 2017-09-21
CN108778333A (zh) 2018-11-09
EP3429622B1 (en) 2021-04-21
US11517621B2 (en) 2022-12-06
JP2019508458A (ja) 2019-03-28
US20230241210A1 (en) 2023-08-03
US12186391B2 (en) 2025-01-07
WO2017157850A1 (en) 2017-09-21
RU2735680C2 (ru) 2020-11-05
EP3429622A1 (en) 2019-01-23
RU2018135290A (ru) 2020-04-15
RU2018135290A3 (enExample) 2020-04-16
US20210162043A1 (en) 2021-06-03
US20200268881A1 (en) 2020-08-27
AU2017233923B2 (en) 2023-10-12
AU2017233923A1 (en) 2018-08-09
US10918715B2 (en) 2021-02-16
US20190076523A1 (en) 2019-03-14
ES2881201T3 (es) 2021-11-29
EP3851123A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL259110A (en) Treatment of osteoarthritis
SG11201609652RA (en) Treatment of polybacterials infections
SG11201702688UA (en) Methods of treating rsv infections
SG11201609993YA (en) Treatment of immune disorders
IL263835A (en) Exosome-guided treatment of cancer
IL246880A0 (en) Tumor treatment
GB201416832D0 (en) Methods of treatment
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL265259A (en) Treatment of multiple sclerosis with chs-131
IL260094A (en) Treatment of hand eczema
IL253773B (en) Treatment of dystrophy of the facial, back and arm muscles
PL3356577T3 (pl) Obróbka w kąpieli wytrawiającej
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
SMT202300391T1 (it) Trattamento della polmonite
GB201515244D0 (en) Treatment of inflammatory disease or condition
GB201514729D0 (en) Treatment of haemorrhoids
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
GB201516418D0 (en) Treatment of acute inflammatory disorders
EP3122363A4 (en) Treatment of autism
GB201510870D0 (en) Treatment of infarction
GB201522257D0 (en) Treatment of autism
GB201505633D0 (en) Novel treatment of STIs
GB201621398D0 (en) Treatment of emt-associated disease